Nautilus Biotechnology Inc (NAUT)
2.56
-0.07
(-2.66%)
USD |
NASDAQ |
Jun 14, 16:00
2.55
-0.01
(-0.39%)
After-Hours: 20:00
Nautilus Biotechnology Enterprise Value: 139.31M for June 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 14, 2024 | 139.31M |
| June 13, 2024 | 148.08M |
| June 12, 2024 | 171.88M |
| June 11, 2024 | 151.84M |
| June 10, 2024 | 146.83M |
| June 07, 2024 | 144.32M |
| June 06, 2024 | 154.34M |
| June 05, 2024 | 141.82M |
| June 04, 2024 | 141.82M |
| June 03, 2024 | 158.10M |
| May 31, 2024 | 161.86M |
| May 30, 2024 | 149.33M |
| May 29, 2024 | 141.82M |
| May 28, 2024 | 141.82M |
| May 24, 2024 | 155.60M |
| May 23, 2024 | 149.33M |
| May 22, 2024 | 165.62M |
| May 21, 2024 | 165.62M |
| May 20, 2024 | 174.39M |
| May 17, 2024 | 188.17M |
| May 16, 2024 | 184.41M |
| May 15, 2024 | 178.14M |
| May 14, 2024 | 176.89M |
| May 13, 2024 | 160.61M |
| May 10, 2024 | 161.86M |
| Date | Value |
|---|---|
| May 09, 2024 | 169.38M |
| May 08, 2024 | 153.09M |
| May 07, 2024 | 164.37M |
| May 06, 2024 | 171.88M |
| May 03, 2024 | 155.60M |
| May 02, 2024 | 153.09M |
| May 01, 2024 | 166.87M |
| April 30, 2024 | 136.81M |
| April 29, 2024 | 140.57M |
| April 26, 2024 | 130.54M |
| April 25, 2024 | 114.26M |
| April 24, 2024 | 119.27M |
| April 23, 2024 | 130.54M |
| April 22, 2024 | 121.78M |
| April 19, 2024 | 126.79M |
| April 18, 2024 | 111.75M |
| April 17, 2024 | 123.03M |
| April 16, 2024 | 134.30M |
| April 15, 2024 | 126.79M |
| April 12, 2024 | 128.04M |
| April 11, 2024 | 148.08M |
| April 10, 2024 | 139.31M |
| April 09, 2024 | 148.08M |
| April 08, 2024 | 156.85M |
| April 05, 2024 | 153.09M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-64.65M
Minimum
Dec 16 2022
1.288B
Maximum
Jun 10 2021
207.73M
Average
166.91M
Median
Feb 01 2022
Enterprise Value Benchmarks
| CEL-SCI Corp | 65.10M |
| AIM ImmunoTech Inc | 15.35M |
| IGC Pharma Inc | 25.36M |
| NovaBay Pharmaceuticals Inc | 3.382M |
| Protalix BioTherapeutics Inc | 55.51M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -18.73M |
| Total Expenses (Quarterly) | 21.61M |
| EPS Diluted (Quarterly) | -0.15 |
| Earnings Yield | -21.48% |